NASDAQ: TNYA
Tenaya Therapeutics Inc Stock Forecast, Predictions & Price Target

Analyst price target for TNYA

Based on 5 analysts offering 12 month price targets for Tenaya Therapeutics Inc

Min Forecast
$5.00+991.7%
Avg Forecast
$8.60+1,777.73%
Max Forecast
$18.00+3,830.13%

Should I buy or sell TNYA stock?

Based on 5 analysts offering ratings for Tenaya Therapeutics Inc.

Strong Buy
Strong Buy
3 analysts 60%
Buy
2 analysts 40%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their TNYA stock forecasts and price targets.

TNYA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-31
lockedlocked$00.00+00.00%2025-03-13Find Out Why
lockedlocked$00.00+00.00%2025-03-12Find Out Why
lockedlocked$00.00+00.00%2025-03-12Find Out Why
lockedlocked$00.00+00.00%2025-02-03

1 of 1

Forecast return on equity

Is TNYA forecast to generate an efficient return?

Company
340.98%
Industry
153.19%
Market
81.87%
TNYA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TNYA forecast to generate an efficient return on assets?

Company
263.97%
Industry
36.07%
TNYA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TNYA earnings per share forecast

What is TNYA's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
-$0.70
Avg 2 year Forecast
-$0.71
Avg 3 year Forecast
$0.41

TNYA revenue forecast

What is TNYA's revenue in the next 3 years based on estimates from 1 analyst?

Avg 1 year Forecast
$15.0M
Avg 2 year Forecast
$17.5M
Avg 3 year Forecast
$284.4M

TNYA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TNYA$0.46$8.60+1,777.73%Strong Buy
OKYO$1.17$7.00+498.29%Buy
SPRO$0.73$5.00+589.66%Buy
MRSN$0.33N/AN/A
RNTX$1.78N/AN/A

Tenaya Therapeutics Stock Forecast FAQ

Is Tenaya Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 5 Wall Street analysts covering (NASDAQ: TNYA) stock is to Strong Buy TNYA stock.

Out of 5 analysts, 3 (60%) are recommending TNYA as a Strong Buy, 2 (40%) are recommending TNYA as a Buy, 0 (0%) are recommending TNYA as a Hold, 0 (0%) are recommending TNYA as a Sell, and 0 (0%) are recommending TNYA as a Strong Sell.

If you're new to stock investing, here's how to buy Tenaya Therapeutics stock.

What is TNYA's earnings growth forecast for 2025-2027?

(NASDAQ: TNYA) Tenaya Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.

Tenaya Therapeutics's earnings in 2025 is -$111,129,000.On average, 8 Wall Street analysts forecast TNYA's earnings for 2025 to be -$60,983,796, with the lowest TNYA earnings forecast at -$110,354,134, and the highest TNYA earnings forecast at -$44,667,149. On average, 5 Wall Street analysts forecast TNYA's earnings for 2026 to be -$62,534,009, with the lowest TNYA earnings forecast at -$108,602,481, and the highest TNYA earnings forecast at -$46,418,802.

In 2027, TNYA is forecast to generate $35,619,862 in earnings, with the lowest earnings forecast at -$55,177,067 and the highest earnings forecast at $206,695,045.

What is TNYA's revenue growth forecast for 2025-2027?

(NASDAQ: TNYA) Tenaya Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.37%.

Tenaya Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast TNYA's revenue for 2025 to be $1,313,739,690, with the lowest TNYA revenue forecast at $1,313,739,690, and the highest TNYA revenue forecast at $1,313,739,690. On average, 2 Wall Street analysts forecast TNYA's revenue for 2026 to be $1,532,696,305, with the lowest TNYA revenue forecast at $1,313,739,690, and the highest TNYA revenue forecast at $1,751,652,920.

In 2027, TNYA is forecast to generate $24,904,125,390 in revenue, with the lowest revenue forecast at $4,379,132,300 and the highest revenue forecast at $45,429,118,480.

What is TNYA's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: TNYA) forecast ROA is 263.97%, which is higher than the forecast US Biotechnology industry average of 36.07%.

What is TNYA's Price Target?

According to 5 Wall Street analysts that have issued a 1 year TNYA price target, the average TNYA price target is $8.60, with the highest TNYA stock price forecast at $18.00 and the lowest TNYA stock price forecast at $5.00.

On average, Wall Street analysts predict that Tenaya Therapeutics's share price could reach $8.60 by Mar 31, 2026. The average Tenaya Therapeutics stock price prediction forecasts a potential upside of 1,777.73% from the current TNYA share price of $0.46.

What is TNYA's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: TNYA) Tenaya Therapeutics's current Earnings Per Share (EPS) is -$1.31. On average, analysts forecast that TNYA's EPS will be -$0.70 for 2025, with the lowest EPS forecast at -$1.26, and the highest EPS forecast at -$0.51. On average, analysts forecast that TNYA's EPS will be -$0.71 for 2026, with the lowest EPS forecast at -$1.24, and the highest EPS forecast at -$0.53. In 2027, TNYA's EPS is forecast to hit $0.41 (min: -$0.63, max: $2.36).

What is TNYA's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: TNYA) forecast ROE is 340.98%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.